The possibility of adapting European clinical and economic models for use in the Russian routine practice to calculate the treatment of patients with diabetes mellitus type 2

Published: 2017-05-26

    Foreign experience
  • The cost of the type 2 diabetes mellitus (DM2) treatment with dapagliflozin as a first-line drug, its subsequent combination with metformin and then switching to insulin therapy, were 297 321 068 rubles. This calculation based on the prospective modelling with a 25 year prognosis horizon in the cohort of 1,000 patients. In case of the first-line saxagliptin application, its following combination with metformin and then switching to insulin therapy, the costs were 297 733 828 rubles, that is at 412,760 rubles more than first-line dapagliflozin strategy. A cost-effectiveness analysis of the first-line dapagliflozin strategy in comparing with the saxagliptin treatment is not highly sensitive to changes in the price that are within 10%. In this range of price changes, the dapagliflozin strategy can be considered even more cost-effective achieving 141.38 rubles for QALY gained with an increase in the price of dapagliflozin by 10% and 244.05 rubles / QALY, while the price of saxagliptin decreases by 10%.

    Authors: Zelenova O. V. [3] Zhilina V. V. [3] Kreknina E. A. [4] Sannikov A. I. [1] Belyakova N. V. [3]

    Tags: cost-effectiveness2 diabetes mellitus type 2 (dm2)1 direct costs3 sensitivity analysis1 treatment strategy1

Articles
11

Authors
28

Pages
80

Last issues

Archive >
2017

«Мз» №5 2017

Дата выпуска: 2017-05-25

33

«Мз» №4 2017

Дата выпуска: 2017-01-02

28

«Мз» №2 2017

Дата выпуска: 2017-02-02

109

«Мз» №1 2017

Дата выпуска: 2017-01-10

81